Cory Renauer is an Analyst at BioSpace. He focuses on investing in healthcare and fintech stocks, aiming to simplify complex financial topics to empower everyday investors in making informed decisions. Cory's insights have been featured in prominent outlets including Yahoo Finance, Nasdaq, and The Motley Fool.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Cory's articles primarily focus on investment analysis, with a particular emphasis on healthcare and pharmaceutical companies, as well as high-yield dividend stocks. He also covers stock market trends and specific stock recommendations based on data-driven analyses.
For effective outreach to Cory Renauer, consider providing data-backed insights into the performance of healthcare and pharmaceutical companies or high-yield dividend stocks. If you have expertise in analyzing investment opportunities within these sectors, particularly with reference to specific stocks or broader market trends, your pitch is likely to be well-received.
It's important that any information provided is backed by credible data and rigorous analysis given Cory's strong reliance on cited data in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
This global oilfield services provider saw insider buying after a year of standout share gains and continued expansion across key markets.
By: Cory Renauer
This animal health provider, serving global livestock markets, reported a notable insider buy in its latest SEC filing.
By: Cory Renauer
This offshore drilling contractor saw a recent insider buy as it maintains a global presence serving major and independent energy clients.
By: Cory Renauer
Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Specializing in AI-driven lending platforms, this fintech innovator was the focus of a recent insider buy, according to SEC filings.
By: Cory Renauer
This clinical-stage biotech focused on GPCR-targeted therapies reported a notable insider sale amid rapid share price appreciation.
By: Cory Renauer
Accelerant Holdings connects specialty insurance underwriters with risk capital; a key insider recently trimmed their stake, filings show.
By: Cory Renauer
Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
By: Cory Renauer
This global battery and automotive care supplier reported a notable insider buy amid ongoing accumulation and steady dividend payouts.
By: Cory Renauer
This 4D LiDAR innovator for autonomous systems reported a notable insider sale amid a year of declining direct holdings.
